PMID- 31981048
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1559-0267 (Electronic)
IS  - 1080-0549 (Linking)
VI  - 59
IP  - 2
DP  - 2020 Oct
TI  - The Current State of Biologic Therapies for Treatment of Refractory Asthma.
PG  - 195-207
LID - 10.1007/s12016-020-08776-8 [doi]
AB  - Asthma is a heterogeneous disease, with the immune processes behind the chronic 
      inflammation underlying this disorder differing between the various identified 
      asthma endotypes. In addition to heterogeneity in underlying disease 
      pathophysiology, asthmatics fall across a broad spectrum of disease severity and 
      can vary greatly in their response to convention asthma therapies. A small 
      percentage of patients with severe persistent asthma will remain uncontrolled 
      despite treatment with high-dose inhaled corticosteroids and a long-acting 
      beta-agonist. Less than two decades ago, there were few options for these 
      treatment-refractory asthmatics beyond chronic systemic steroids, with their 
      myriad of treatment-limiting side effects. However, in recent years, there have 
      been a growing number of Food and Drug Administration (FDA)-approved biologic 
      medications with targets that include immunoglobulin E (IgE), interleukin-5 
      (IL-5), the IL-5 receptor and the IL-4/IL-13 receptor-alpha subunit. The current 
      FDA-approved biologics for severe persistent asthma are omalizumab, mepolizumab, 
      reslizumab, benralizumab, and dupilumab. These monoclonal antibodies have been 
      shown to improve asthma control, decrease asthma exacerbations and decrease 
      glucocorticoid dependence in certain subsets of patients with asthma. The optimal 
      biologic for treatment of severe asthma varies from patient to patient, depending 
      on the underlying pathophysiology of the patient's disease. For each of these 
      medications, there are certain biomarkers that can help predict whether a patient 
      is likely to respond favorably to the medication. This review will discuss the 
      currently approved biologics for severe persistent asthma, including their 
      indications, efficacy and side effects.
FAU - Mavissakalian, Matthew
AU  - Mavissakalian M
AD  - Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Jacobs 
      School of Medicine and Biomedical Sciences, University at Buffalo, 100 High 
      Street, Buffalo, NY, 14203, USA.
FAU - Brady, Sean
AU  - Brady S
AUID- ORCID: 0000-0001-6316-3577
AD  - Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Jacobs 
      School of Medicine and Biomedical Sciences, University at Buffalo, 100 High 
      Street, Buffalo, NY, 14203, USA. spbrady@buffalo.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Anti-Asthmatic Agents)
SB  - IM
MH  - Anti-Asthmatic Agents/pharmacology/therapeutic use
MH  - Asthma/diagnosis/etiology/*therapy
MH  - *Biological Therapy/adverse effects/methods
MH  - Clinical Decision-Making
MH  - Clinical Trials as Topic
MH  - Comorbidity
MH  - Disease Management
MH  - Disease Susceptibility
MH  - Drug Development
MH  - Drug Resistance
MH  - Humans
MH  - Prognosis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Asthma
OT  - Asthma medications
OT  - Benralizumab
OT  - Biologic therapies
OT  - Dupilumab
OT  - Eosinophils
OT  - IL-13
OT  - IL-4
OT  - IL-5
OT  - IgE
OT  - Mepolizumab
OT  - Omalizumab
OT  - Reslizumab
OT  - Thymic stromal lymphopoietin (TSLP)
EDAT- 2020/01/26 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/01/26 06:00
PHST- 2020/01/26 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2020/01/26 06:00 [entrez]
AID - 10.1007/s12016-020-08776-8 [pii]
AID - 10.1007/s12016-020-08776-8 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2020 Oct;59(2):195-207. doi: 
      10.1007/s12016-020-08776-8.